In a first, a subcutaneously administered RNA interference medicine crossed into the brain and plummeted levels of a protein ...

In the Phase 1/2a trial, patients receiving Arrowhead’s drug saw an average 73% reduction in tau protein levels in ...

During the special, Bill will look at the latest research into the disease and we will talk to the families who are helping ...

Study raises concerns about glucosamine and Alzheimer’s disease, linking supplements to faster progression from mild ...

Walks to End Alzheimer's are set across the Capital Region as local leaders share why the events matter for families facing ...

Forecast for rapid growth by 2033, with disease-modifying therapies driving sales – and healthcare systems confronting the cost of access.

A study found plasma %p-tau217 reliably identified elevated brain amyloid across diverse groups, supporting its use in ...

Dementia and Alzheimer’s disease are closely related, but the terms describe different things. Dementia is a pattern of problems with memory, thinking or behaviour that interferes with daily life, ...

Award to Dr. Walter Swardfager, from Sunnybrook Research Institute, will support a proof-of-mechanism clinical trial ...

They differ from traditional risk factors associated with the late-onset form of the disease.

For decades, scientists have focused on amyloid beta as a major culprit behind Alzheimer’s disease, spending billions of dollars developing treatments that have often delivered disappointing results.

UMBC is contributing to a multi-institution research project, funded by the Advanced Research  Projects Agency for Health ...